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Background: Thyroid cancer is the most common endocrine malignancy, and many patients with metastatic
differentiated thyroid cancer (DTC), poorly differentiated thyroid cancer (PDTC), and anaplastic thyroid cancer (ATC)
fail to respond to conventional therapies, resulting in morbidity and mortality. Additional therapeutic targets and
treatment options are needed for these patients. We recently reported that peroxisome proliferator-activated receptor
gamma (PPARγ) is highly expressed in ATC and confers an aggressive phenotype when overexpressed in DTC cells.
Methods: Microarray analysis was used to identify downstream targets of PPARγ in ATC cells. Western blot analysis and
immunohistochemistry (IHC) were used to assess thioredoxin interacting protein (TXNIP) expression in thyroid cancer
cell lines and primary tumor specimens. Retroviral transduction was used to generate ATC cell lines that overexpress
TXNIP, and assays that assess glucose uptake, viable cell proliferation, and invasion were used to characterize the in vitro
properties of these cells. An orthotopic thyroid cancer mouse model was used to assess the effect of TXNIP
overexpression in ATC cell lines in vivo.
Results: Using microarray analysis, we show that TXNIP is highly upregulated when PPARγ is depleted from ATC cells.
Using Western blot analysis and IHC, we show that DTC and ATC cells exhibit differential TXNIP expression patterns.
DTC cell lines and patient tumors have high TXNIP expression in contrast to low or absent expression in ATC cell lines
and tumors. Overexpression of TXNIP decreases the growth of HTh74 cells compared to vector controls and inhibits
glucose uptake in the ATC cell lines HTh74 and T238. Importantly, TXNIP overexpression in T238 cells results in
attenuated tumor growth and decreased metastasis in an orthotopic thyroid cancer mouse model.
Conclusions: Our findings indicate that TXNIP functions as a tumor suppressor in thyroid cells, and its downregulation
is likely important in the transition from differentiated to advanced thyroid cancer. These studies underscore the
potential of TXNIP as a novel therapeutic target and prognostic indicator in advanced thyroid cancer.
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Thyroid cancer is the most common endocrine malignancy,
and it is estimated that nearly 63,000 new cases of thyroid
cancer will be diagnosed in the United States in 2014 [1].
Although the majority of these patients have well-
differentiated thyroid cancer and respond favorably to con-
ventional therapies (surgery with or without radioactive
iodine I131 therapy and suppression therapy with thyroid
hormone), a significant minority of patients develops* Correspondence: Jennifer.Morrison@ucdenver.edu
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unless otherwise stated.advanced disease that is resistant to standard treatments.
For the minority of individuals who develop anaplastic
thyroid cancer (ATC), an aggressive and undifferentiated
form of thyroid cancer, the prognosis is very poor and
median survival is 3–5 months [2,3]. The mechanisms
underlying the development of poorly differentiated thyroid
cancer (PDTC) and ATC are incompletely understood.
Therapeutic options for these patients are limited, and
prognosis remains dismal. This is an area for which further
research and drug/therapy development is critically needed.
We recently reported that peroxisome proliferator-
activated receptor gamma (PPARγ) confers an aggressive
phenotype in thyroid cancer cells [4]. Nuclear PPARγal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(DTC) cell lines and high in ATC cell lines. When
PPARγ was overexpressed in the DTC cell line BCPAP,
in vitro proliferation and invasive capacity were in-
creased. Furthermore, when PPARγ was depleted from
ATC cells, in vitro proliferation and invasive capacity were
inhibited and tumor growth was inhibited in two in vivo
murine cancer models (an orthotopic thyroid model and a
flank xenograft model). These data challenge the widely-
held assumption that PPARγ is a tumor suppressor and
suggest that PPARγ may mediate the aggressive phenotype
that develops as part of the transition from DTC to PDTC
and ATC.
In the studies presented here, we show that TXNIP, the
gene encoding thioredoxin interacting protein (TXNIP),
is a negatively-regulated downstream target of PPARγ.
TXNIP is a negative regulator of cell growth and metabol-
ism [5-11]. It modulates cellular redox status by binding
to and inhibiting thioredoxin, a principal component of
the cell’s antioxidant system [12-14]. Furthermore, via its
negative regulation of thioredoxin, TXNIP can inhibit in-
vasion and metastasis and promote a pro-apoptotic cellu-
lar environment [15-20]. TXNIP has been shown to be a
tumor suppressor in cancer [8,21-28], but its role in thy-
roid cells or in thyroid cancer has not been investigated.
In this current study, we show that TXNIP is highly
expressed in DTC and low or undetectable in ATC and
appears to be a novel tumor suppressor in thyroid cancer.
Results
TXNIP is upregulated in PPARγ-depleted ATC cells
We previously reported that PPARγ confers an aggressive
phenotype in thyroid cancer cells [4]. To investigate down-
stream mediators of these effects, a discovery-based micro-
array approach was used to compare mRNA expression
levels in HTh74 ATC cells expressing a PPARγ-specific
shRNA compared to a scrambled control. The most
highly up- and down-regulated genes are shown in
Table 1. PPARG was the most highly downregulated gene,
which is consistent with the use of a PPARγ-specific
shRNA. The most highly upregulated gene in the PPARγ-
depleted HTh74 cells was thyroid peroxidase, an enzyme
critical to synthesis of thyroid hormone. Interestingly,
TXNIP was the second most highly upregulated gene in
the PPARγ-depleted ATC cells (>10-fold). TXNIP is a
known tumor suppressor whose role in thyroid cancer
has never been reported. Western blot analysis of whole
cell extracts confirms that TXNIP is also upregulated at
the protein level when PPARγ expression is knocked
down in the HTh74 ATC cells (Figure 1A). These data
imply that TXNIP downregulation in HTh74 cells is a
downstream consequence of high nuclear PPARγ expres-
sion, as TXNIP expression is increased when HTh74 cells
are depleted of PPARγ. These data are consistent with apreviously published report that the TXNIP promoter
contains multiple PPARγ binding sites and that TXNIP
expression is negatively regulated by binding of PPARγ
to the TXNIP promoter and by treatment with PPARγ
agonists [29].
TXNIP is expressed at high levels in DTC cells and tissues
compared with ATC, and TXNIP expression correlates
inversely with glucose uptake
We next investigated whether there is differential TXNIP
expression in DTC versus ATC cells. Western blot analysis
revealed high TXNIP expression in the DTC cell lines
TPC-1, MDA-T41, and BCPAP in contrast to low or un-
detectable expression in the ATC cell lines HTh74, C643,
Ocut-2, and 8505C (Figure 1B). This disparate TXNIP ex-
pression between DTC and ATC cell lines, however, was
not absolute. The ATC cell lines T238 and TJH11T had
levels of TXNIP expression comparable to some DTC
cells, whereas the DTC cell line K1 had lower TXNIP ex-
pression in comparison to the other DTC cell lines. Simi-
lar trends were observed at the mRNA level (data not
shown).
TXNIP is a known binding partner and inhibitor of the
cellular antioxidant and tumor promoter thioredoxin
(Trx) [12,14]. Thioredoxin may be localized to the cyto-
plasm or nucleus (Trx-1) where it can function as a
cofactor, detoxify reactive oxygen species, or modulate
the activity of transcription factors, or to mitochondria
(Trx-2), and high Trx-1 expression is associated with
more aggressive disease in other cancer types [30-36].
As TXNIP is a negative regulator of Trx and disparate
TXNIP expression was observed between the panels of
DTC and ATC cell lines, we sought to identify differ-
ences in Trx-1 expression patterns between the two
groups. Immunoblot analysis revealed no clear differ-
ences in Trx-1 expression levels between DTC and ATC
(Figure 1B).
TXNIP is also a known inhibitor of glucose uptake
[5,7,11]. We, therefore, investigated whether differential
TXNIP expression correlates with differences in glucose
uptake. Analysis of glucose uptake of two ATC and two
DTC cell lines was performed, and the ATC cell line
HTh74, which has the lowest TXNIP levels of the exam-
ined cell lines, had the highest level of glucose uptake
(Figure 1C). Interestingly, the ATC cell line T238 had
glucose uptake at levels comparable to that observed
with the two DTC cell lines TPC-1 and MDA-T41. This
finding is consistent with a higher level of TXNIP ex-
pression in this cell line (Figure 1B).
We next investigated whether TXNIP was differentially
expressed at the tumor tissue level. Immunohistochemis-
try to detect TXNIP protein expression was performed on
paraffin-embedded tumor blocks of 13 well-differentiated
primary papillary thyroid cancer (PTC) tumors and 8 ATC
Table 1 List of highly upregulated and downregulated genes when PPARγ expression is depleted from the HTh74 ATC
cell line
Gene expression changes in PPARγ-depleted HTh74 cells
Gene Description Fold change
Upregulated
TPO Thyroid peroxidase 11.7
TXNIP Thioredoxin interacting protein 10.7
C1orf168 Chromosome 1 open reading frame 168 10.2
NFASC Neurofascin homolog (chicken) 7.6
SFRP4 Secreted frizzled-related protein 4 7.6
LOC727770 Similar to ankyrin repeat domain 20 family, member A1 7.2
ASTN1 Astrotactin 1 7.1
Downregulated
PPARG Peroxisome proliferator-activated receptor gamma −9.2
EVI2B Ecotropic viral integration site 2B −7.5
LOC643201 Hypothetical protein LOC643201 −7.2
NQO1 NAD(P)H dehydrogenase, quinone 1 −7.1
ACTG2 Actin, gamma 2, smooth muscle, enteric −6.3
ARHGAP26 Rho GTPase activating protein 26 −6.0
RLN2 Relaxin 2 −5.7
Stable cell lines were generated via transduction of the ATC cell line HTh74 with lentivirus encoding PPARγ-specific shRNA or scrambled control followed by
selection in puromycin 0.5 μg/mL. Prepared RNA was then subjected to microarray analysis. Genes whose mRNA levels varied by greater than 5-fold are shown in
the table along with fold change.
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magnification are shown for PTC (Figure 2A-B) and ATC
(Figure 2C). TXNIP expression was undetectable in 63%
of ATC specimens in contrast to 15% of PTC specimens,
though there was one ATC specimen that exhibited high
TXNIP staining. This differential TXNIP expression be-
tween PTC and ATC is similar to the pattern observed
with the thyroid cancer cell lines (Figure 1B). Therefore,
loss of or absence of TXNIP expression appears to correl-
ate with more aggressive thyroid cancer in cell lines and
tumor tissue.
TXNIP overexpression in the ATC cells attenuates in vitro
glucose uptake and growth
Based on its differential expression in DTC and ATC, we
predicted that TXNIP acts as a tumor suppressor in thy-
roid cells and that its downregulation plays an important
role in the development of an aggressive thyroid cancer
phenotype. To further investigate this hypothesis, we re-
expressed TXNIP in ATC cell lines. HTh74 and T238
ATC cell lines were transduced with a retroviral vector
encoding human TXNIP. Western blot analysis verified
increased TXNIP expression in the transduced HTh74
(Figure 3A) and T238 (Figure 3B) cell lines compared to
control cells transduced with empty vector. As a func-
tional read out of TXNIP expression, we assessed glucose
uptake in the stable cell lines. TXNIP overexpression sig-
nificantly inhibited glucose uptake in both the HTh74 andT238 cell lines (Figure 3C and 3D, respectively), consistent
with its known function of glucose uptake inhibition in
other tissues.
To assess the effect of TXNIP overexpression on the
growth of these ATC cell lines, viable cell proliferation
assays were performed under standard growth condi-
tions. TXNIP overexpression resulted in slowed growth
of HTh74 cells by 37% (Figure 4A). Interestingly, how-
ever, TXNIP overexpression in T238 cells had no effect
on the in vitro growth rate (Figure 4B). The reasons for
the observed differences in TXNIP-mediated growth ef-
fects between these two cell lines are unclear, however,
there are a few potential causes or factors that might
contribute to this discrepancy. The baseline proliferation
rate of parental T238 cells is much higher than parental
HTh74 cells (data not shown), and this may obscure our
ability to detect more subtle growth inhibitory effects with
TXNIP overexpression in the T238 cell line. Alternatively,
differential pathway activation might explain the in vitro
growth differences between T238 and HTh74 cells and
the ability of T238 cells to circumvent TXNIP-mediated
growth deceleration. The T238 parental cell line has some
basal TXNIP expression, and these cells have likely ac-
quired the ability to resist some of the in vitro growth
inhibitory effects of TXNIP via other mechanisms. In
addition, the standard growth media used in propagation
of these cell lines provides supplemental glutamine and













Figure 1 TXNIP is highly expressed in DTC cell lines and low or undetectable in ATC cell lines, and glucose uptake is inversely
proportional to TXNIP expression levels. (A) HTh74 cells were transduced with lentivirus expressing a PPARγ-specific shRNA or scrambled
control, and stable pools were generated under antibiotic selection. Western blot analysis of nuclear lysates (top immunoblot) reveals PPARγ
expression levels in the transduced cells. Using Western blot analysis of whole cell lysates, TXNIP and β-actin (loading control) were detected
using specific antibodies. Nonspecific band is indicated by “ns”. (B) Western blot analysis for TXNIP, Trx-1, and β-actin (loading control) were
performed on whole cell lysates prepared from a panel of DTC and ATC cell lines grown under standard conditions. (C) Glucose uptake assays
were performed. Each condition was performed in triplicate per experiment, and each experiment was performed at least three times. Nonspecific
glucose uptake as determined by parallel treatment of a subset with cytochalasin B was subtracted from measurements. Data from all experiments
were combined, and glucose uptake from each cell line was normalized to levels of HTh74 (average set at 1). Normalized averages are plotted, and
error bars indicate SEM. ***p <0.0001, **p <0.001.
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TXNIP overexpression in vitro. These potential limitations
of in vitro assay systems, which do not adequately recap-
itulate in vivo tumor conditions, underscore the import-
ance of further evaluation in an in vivo model system. In
addition to proliferation assays, we performed invasion as-
says using an in vitro Matrigel invasion model [37], and
TXNIP overexpression resulted in a trend towards de-
creased invasion in both cell lines but this did not reach
statistical significance (Figure 4C-D).
TXNIP expression in ATC cells results in attenuated tumor
growth and metastasis in an in vivo orthotopic thyroid
cancer mouse model
Finally, we examined the effect of TXNIP overexpression in
an in vivo orthotopic tumor model. The orthotopic thyroid
cancer mouse model is a well-established model that closely
mimics the features of human thyroid cancer with regard
to growth and metastases than does the more commonly-
used subcutaneous flank xenograft model [4,38-41]. Tumorcells expressing luciferase-IRES-GFP were injected into the
right thyroid lobe and monitored weekly by IVIS imaging
for tumor establishment and growth. TXNIP overex-
pression in the T238 cell line resulted in attenuated bio-
luminescence compared to vector control (Figure 5A-B),
and resultant tumor volumes were significantly smaller
(Figure 5C). Though there was a significant attenuation in
bioluminescence as well as a trend toward smaller tumors
with the TXNIP-expressing HTh74 cells compared to
vector controls, the final tumor volumes were not sig-
nificantly different (data not shown).
In our experience, T238 cells in this orthotopic model
frequently result in lung metastases (unpublished data).
To determine if TXNIP overexpression affected distant
metastatic spread in this orthotopic model, lungs were
collected at necropsy and snap-frozen, homogenized,
and RNA was subsequently isolated and subjected to
qRT-PCR to detect GFP expression, a marker of lung
metastases in this model. Metastatic tumor burden was
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Figure 2 TXNIP is expressed in primary DTC tumors but is low
or undetectable in ATC tumors. Immunohistochemistry was
performed using a TXNIP-specific primary antibody or normal mouse
IgG control and a horseradish peroxidase tagged secondary antibody
on a panel of 13 PTC and 8 ATC patient specimens. Two representative
PTC (A-B) and one ATC (C) specimen stains are shown at 20X and 60X
power. Positive staining is indicated by brown coloring, though staining
of colloid is nonspecific. Staining was quantitated by a pathologist
(S. B. S.), and intensity of staining was scored from absent (0) to high to
(3+), followed by percent of tumor positivity.
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(Figure 5D). Control mice with no tumor cells injected
had no detectable GFP mRNA in their lung tissues.
Discussion
In this report, we identified TXNIP as a novel tumor sup-
pressor in thyroid cancer. TXNIP is highly upregulated
when PPARγ, which we have previously shown to be a
tumor promoter [4], is depleted from ATC cells. Further-
more, DTC cell lines and primary PTC tumors have high
endogenous TXNIP levels, whereas TXNIP expression is
low or absent in ATC cell lines and primary tumor speci-
mens. This TXNIP expression pattern is opposite to what
we previously reported with PPARγ, which is highly
expressed in ATC cell lines and absent in DTC cell lines
and whose forced expression confers a more aggressive
phenotype in thyroid cancer cells in vitro and in vivo [4].
These data are consistent with a previously published re-
port that TXNIP is a negatively-regulated target of PPARγ
[29]. Therefore, TXNIP expression appears to be downreg-
ulated or lost in the progression from well-differentiated
thyroid tumors to more aggressive, undifferentiated tu-
mors. TXNIP has been shown to be a tumor suppressor in
other cell types, and our results here show for the first
time that it serves a similar function in thyroid cells.
The novel finding that TXNIP expression is lost
in the progression from well-differentiated PTC toundifferentiated, aggressive ATC is consistent with our hy-
pothesis that TXNIP is a tumor suppressor in thyroid
cancer. Patients with well-differentiated PTC respond
well to conventional therapy and have an excellent overall
survival rate. Poorly-differentiated PTC tumors that have
lost the ability to concentrate iodine often fail to respond
to conventional therapy and result in poorer outcomes,
and undifferentiated ATC portends an extremely-poor
prognosis and is generally fatal within 3–5 months [2,3].
The apparent loss of TXNIP expression during the pro-
gression from well-differentiated to poorly-differentiated
and undifferentiated thyroid cancer is consistent with its
role as a tumor suppressor in thyroid cells. Loss of TXNIP
expression has been reported to correlate with more ag-
gressive disease, advanced stage, and poorer prognosis in
breast, gastric, colorectal, and bladder cancers, as well as
diffuse large B-cell lymphoma [23,24,42-47], and TXNIP
mRNA expression has been shown to be inversely propor-
tional to melanoma progression [27]. TXNIP expression
in cancer may be downregulated through epigenetic, tran-
scriptional, post-transcriptional, or translational mecha-
nisms (reviewed by Zhou et al. [21]). Though the tumor
promoter and cellular antioxidant Trx-1, which is inhib-
ited by TXNIP, has been shown to confer more aggressive
disease in other cancers [30-34], our data failed to show
differences in Trx-1 expression levels between DTC and
ATC cells.
Overexpression of TXNIP in the HTh74 ATC cell line
resulted in slowed in vitro growth. This negative growth
regulatory effect has been seen in other systems as well.
TXNIP overexpression in the human gastric carcinoma
cell lines AGS, SNU-16, and SNU-620, the promyelocy-
tic leukemia cell line HL-60, and HTLV-I-positive T cells
led to growth reduction in vitro [8,22,48]. Lung fibro-
blasts from TXNIP knockout mice proliferate at a faster
rate than wild-type, implying that loss of TXNIP promotes
or allows for enhanced proliferation [9]. Interestingly, we
did not observe an in vitro growth inhibitory effect in the
T238 cell line, which has some basal endogenous TXNIP
expression. It is likely that the effects of TXNIP on cell
growth and proliferation are cell-context dependent
and might be circumvented through activation of al-
ternative mitogenic pathways. Furthermore, in vitro
cell culture conditions do not adequately recapitulate the
tumor microenvironment and contributions of paracrine-
mediated signaling, underscoring the importance of in vivo
studies. In accordance with this potential limitation, Gold-
berg and colleagues failed to see slowed in vitro growth
of melanoma cells transfected with TXNIP though when
injected in an orthotopic flank model in nude mice, slowed
tumor growth/development was observed [27]. Although
we observed a trend toward decreased invasion by TXNIP
overexpression in two ATC cell lines, this effect did not














Figure 3 TXNIP overexpression in ATC HTh74 and T238 cells attenuates glucose uptake. HTh74 and T238 cells were transduced with
retrovirus encoding human TXNIP or vector control as well as a selectable antibiotic resistance marker, and stable pools were generated under
antibiotic selection. Western blot analysis of whole cell lysates with TXNIP- and β-actin-specific antibodies is shown for HTh74 (A) and T238 (B). Glucose
uptake assays were performed as described in Figure 1 using the HTh74 stable cell lines (C) and T238 stable cell lines (D). Data from all experiments
were combined, and glucose uptake from each cell line was normalized to vector control levels (average set at 1). **p = 0.001, ***p <0.0001.
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thyroid cancer model that mimics human thyroid cancer
with regard to growth and metastasis, we show that
TXNIP overexpression in the ATC T238 cell line resulted
in significant attenuation of both tumor growth and pul-
monary metastatic burden. These data support our hy-
pothesis that TXNIP is a tumor suppressor in thyroid
cells. TXNIP has been shown to be a tumor suppressor in
other animal models of cancer as well. A mouse strain
with a spontaneous nonsense mutation in TXNIP has dra-
matically increased incidence of spontaneous hepatocellu-
lar carcinomas (HCC) [25], and TXNIP-knockout mice
develop increased number and size of HCC in a diethylni-
trosamine (DEN)-induced murine model of HCC [28]. In
a murine gastric carcinoma model in which tumors are in-
duced via infection with Helicobacter pylori and cotreat-
ment with N-methyl-N-nitrosourea, concomitant knock
out of TXNIP resulted in increased numbers of tumors,
heightened preneoplastic changes, increased percentage of
malignant tumors, and elevated inflammatory marker ex-
pression compared to control mice with wild-type TXNIP
expression [22]. In a murine model of bladder cancer in
which tumors are induced by treatment with N-butyl-N-
(4-hydroxybutyl) nitrosamine (BBN), genetic deletion of
TXNIP results in accelerated development of high grade
and invasive tumors by ~4 weeks compared to controlswith wild-type expression, however, controls eventually
succumb to tumor development and TXNIP expression in
these tumors has been downregulated by other mecha-
nisms [24].
In the orthotopic ATC model, TXNIP overexpression
also led to a significant reduction in pulmonary metastatic
burden. Inhibition of metastasis conferred by TXNIP
overexpression has been shown in other systems as well.
B16F10 melanoma cells transfected with TXNIP then
injected via tail vein into C57BL/6 mice resulted in de-
creased lung metastases [23]. TXNIP-transfected mel-
anoma cells resulted in fewer metastases in both a nude
mouse flank tumor model and IV tail injection metasta-
sis model relative to vector controls [27]. In human
breast cancer, high TXNIP levels are associated with
longer metastasis-free intervals and better prognosis
than those with low TXNIP expression [43,46]. These
data implicate TXNIP as a tumor suppressor in a variety
of cancers and, for the first time, is now shown to be a
tumor suppressor in thyroid cells.
Curiously, TXNIP overexpression in the ATC cell line
HTh74 resulted in reduced in vitro growth but no sig-
nificant difference on in vivo growth in the orthotopic
thyroid cancer model. Although bioluminescence signals
were attenuated in the TXNIP-expressing HTh74 cells









Figure 4 TXNIP overexpression inhibits in vitro growth of ATC HTh74 cells. Viable cell proliferation assays were performed for stable HTh74
(A) and T238 (B) cell lines. Briefly, 50,000 cells were plated in 6-cm plates, trypsinized and viable cell counts were determined using the ViCell
automated cell counting system. Each time point was performed in duplicate, and lysates were prepared from the day 7 time point to confirm
high TXNIP expression using Western blot analysis. Each experiment was performed at least three times. Mean and SEM are plotted. Closed
squares (∎) indicate vector control cells, and open diamonds (◊) indicate cells with TXNIP overexpression. In vitro invasion assays were performed
on the TXNIP-overexpressing stable HTh74 (C) and T238 (D) cell lines as described in the Methods section. Results from three independent
experiments were combined and normalized to the vector control average and graphed with mean plus SEM. *p <0.01 (Figure 4A), Figure 4B
p = 0.9021, Figure 4C p = 0.3523, Figure 4D p = 0.0754.
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jection of the TXNIP-expressing HTh74 cells compared to
vector controls was observed. TXNIP-overexpressing and
vector control tumors did not look different histologically.
In our prior studies using HTh74 cells in the orthotopic
murine thyroid cancer model system, we have observed
that the in vivo growth rates are slower compared to other
thyroid cancer cell lines (84 days to achieve 100 mm3
tumors compared with 28–35 days in other ATC cell
lines). It is possible that if our study had been tempor-
ally extended, the trend in tumor volume attenuation in
the TXNIP-overexpressing group might have reached
statistical significance. It is also possible that TXNIP
does not play a significant in vivo role on malignant be-
havior in the HTh74 cells, but our in vitro data would
suggest otherwise.
In keeping with the known function of TXNIP as a
glucose uptake inhibitor, we showed that the degree of
glucose uptake was inversely correlated with TXNIP levels
in the examined thyroid cancer cell lines. An interesting
aspect of thyroid cancer biology relates to its properties
on 2-deoxy-2-fluoro-D-glucose positron emission topog-
raphy computed topography (FDG PET/CT) imaging.
FDG PET imaging can be negative in many patients withDTC and distant metastases, and this correlates with a
relatively good prognosis in these patients [49,50]. Less
differentiated PTC and ATC tumors are more likely to be
PET positive, PET positive lesions are more likely to be
resistant to conventional radioactive I131 treatment, and
increased intensity of FDG uptake is associated with a
poorer prognosis and increased mortality [49,50]. The
mechanism underlying this differential glucose uptake
between well-differentiated PTC and ATC is not well
understood. The novel finding that TXNIP expression is
low in ATC is consistent with the observed FDG uptake
on PET/CT in patients with ATC, supporting a critical
role for TXNIP as a metabolic regulator in thyroid can-
cer progression.
In addition to inducing a metabolic shift important to
tumor biology, downregulation of TXNIP has other im-
portant effects in cancer cells that contribute to tumor
promotion and/or progression. TXNIP can reduce tumor
invasion and angiogenesis through inhibition of thiore-
doxin and can directly impact cell survival by promoting a
pro-apoptotic environment [13,15-20]. Independent of its
interaction with thioredoxin, TXNIP also has the ability
to inhibit cell cycle progression by indirectly stabilizing









Figure 5 TXNIP overexpression in ATC T238 cells attenuates tumor growth and metastasis in an in vivo orthotopic murine thyroid
cancer model. T238 cells stably expressing luciferase-IRES-GFP and either TXNIP or empty vector were injected into the right lobe of the thyroid
gland of athymic nude mice with the aid of a dissecting microscope to enhance visualization. Weekly imaging with IVIS after injection of luciferin
was performed to monitor tumor establishment and growth. There were 10–11 mice per group in each experiment, and the experiment was performed
two times. (A) Representative images of one mouse per group imaged by IVIS over time are shown. (B) Quantitation of the bioluminescence from one
experiment is shown with average and SEM. Closed squares (∎) indicate vector control group, and open diamonds (◊) indicate TXNIP group. (C) Final
tumor volumes, as calculated from caliper measurements, from both experiments are combined and plotted with averages and SEM. To assess for lung
metastasis, RNA isolated from whole lungs was subjected to qRT-PCR analysis to assess GFP expression. Data was normalized to 18 s RNA levels, and
averages plus SD were plotted (D). RNA isolated from lungs of mice receiving no tumor cell injections was included as an additional negative control for
GFP expression and is indicated with closed circles (●). *p <0.05, **p =0.0021, ***p <0.001, ****p <0.0001.
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metabolism [6]. Therefore, downregulation of TXNIP in a
tumor has the potential to promote cell survival, growth,
invasion, and metastasis. The exact mechanisms by which
TXNIP exerts its tumor suppressive functions in thyroid
cancer cells are not yet clear. Future studies of the
mechanisms by which TXNIP is expressed and func-
tions in thyroid cancer will improve our understanding
of the progression to advanced thyroid cancer and help
to develop more effective targeted therapies.
Conclusions
In conclusion, we report that TXNIP is a novel tumor
suppressor in thyroid cancer. TXNIP is downregulated
during the progression from well-differentiated thyroid
cancers to poorly differentiated and anaplastic thyroid
cancers. Overexpression of TXNIP in ATC cell lines re-
sulted in slowed in vitro growth and glucose uptake in-
hibition. Importantly, in an in vivo orthotopic murine
thyroid cancer model, TXNIP overexpression attenuated
tumor growth and drastically diminished pulmonary
metastatic tumor burden. These data highlight the im-
portance of TXNIP as a potential therapeutic target and
prognostic marker in advanced thyroid cancer.Methods
Cell lines and maintenance
HTh74 and C643 cells were obtained from Dr. K. Ain
(University of Kentucky, Lexington, KY) with permission
from N. E. Heldin (University Hospital, Uppsala, Sweden).
TPC1 cells were provided by S. Jhiang (Ohio State Uni-
versity, Columbus, OH). BCPAP and 8505C cells were
provided by M. Santoro (Medical School, University of
Naples Federico II, Naples, Italy). TJH11T cells were
obtained from J. A. Copland (Mayo Clinic Comprehensive
Cancer Center, Jacksonville, FL) and were maintained in
RPMI 1640 supplemented with 10% fetal bovine serum
(FBS), non-essential amino acids, 1 mM sodium pyruvate,
1 nM T3, 0.5 μg/mL hydrocortisone, 8 ng/mL epidermal
growth factor, 25 mM HEPES, and 0.1 mg/mL Primocin.
MDA-T41 cells were obtained from G. Clayman (Univer-
sity of Texas MD Anderson Cancer Center, Houston, TX).
K1 cells were provided by D. Wynford-Thomas (Cardiff
University, Cardiff, UK). T238 were obtained from L. Roque
(Instituto Português de Oncologia, Lisboa, Portugal).
Ocut-2 cells were obtained from N. Onoda (Osaka City
University Graduate School of Medicine, Osaka, Japan).
Except for TJH11T cells, all cell lines were maintained
in RPMI 1640 supplemented with 5% FBS. All cells were
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cated by short tandem repeat (STR) profiling as previ-
ously described [51].
PPARγ knockdown and microarray analysis
PPARγ-depleted HTh74 cells and scrambled control cells
were generated as previously described using lentivirus ex-
pressing PPAR-specific shRNA or scrambled control [4].
Total RNA from PPARγ-depleted and scrambled control
cells was isolated using an RNeasy Mini Kit (Qiagen) ac-
cording to the manufacturer’s instructions. Integrity of the
RNA preparation was verified on an Agilent Bioanalyzer
2100. Total RNA (5 μg) of each cell line was used for
microarray analysis using the Human Genome U133 Plus
2.0 Array (Affymetrix), performed by the Gene Expression
Core of the University of Colorado Denver, Anschutz
Medical Campus (Aurora, CO). Gene expression profiles
were normalized by robust multichip analysis (RMA), dif-
ferentially expressed genes were analyzed by fold-change,
using a cut-off of 2-fold, 122 and 198 genes were found
to be up and down-regulated in the knockdown line.
Enrichment analysis of the gene list was performed
using Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) analysis software.
Western blot analysis
Cells were trypsinized and lysed in extraction buffer (EB;
1% Triton X-100, 10 mM Tris pH 7.4, 5 mM ethylenedi-
aminetetraacetic acid (EDTA), 50 mM sodium chloride
(NaCl), 50 mM sodium fluoride, 2 mM sodium orthova-
nadate, and 1X cOmplete protease inhibitors [Roche
Diagnostics]) and clarified by high speed centrifugation
at 4°C. For nuclear PPARγ and Trx-1 expression deter-
mination, cells were fractionated into nuclear and cyto-
solic fractions using the Active Motif Nuclear Extract
system, according to the manufacturer’s instructions.
Whole cell and nuclear protein extracts (25 μg) were di-
luted in Laemmli sample buffer and resolved by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) on 10% gels and transferred to polyvinylidene
difluoride (PVDF) membranes (BioRad). Membranes were
blocked for 1 hour at room temperature in 5% nonfat dry
milk in 20 mmol/L Tris pH 7.4, 128 mmol/L NaCl, 0.1%
Tween 20 (TBST), then incubated overnight in primary
antibody at 4°C. Primary antibodies used for the current
studies include anti-VDUP1 (TXNIP) at 1:500 (rabbit
polyclonal; Invitrogen, catalog # 403700), anti-PPARγ at
1:500 (rabbit polyclonal; Santa Cruz Biotechnology,
catalog # sc-7196), anti-thioredoxin-1 at 1:1,000 (C63C6
rabbit monoclonal; Cell Signaling Technology, catalog
#2429), and anti-β-actin at 1:5,000 (mouse monoclonal;
Sigma-Aldrich, catalog # A5441). After washing in TBST,
membranes were incubated at room temperature for
1 hour in secondary antibodies conjugated to horseradishperoxidase (anti-rabbit at 1:5,000 for TXNIP, PPARγ, and
thioredoxin-1 blots and anti-mouse at 1:10,000 for β-actin
blots; GE Healthcare). SuperSignal West Pico Chemilu-
minescent substrate (Thermo Scientific) was used to de-
tect immunoreactivity. Re-Blot Plus Mild (Millipore) was
used to strip blots for purposes of reprobing with an alter-
nate primary antibody.
Immunohistochemistry
We retrospectively selected formalin-fixed, paraffin-
embedded blocks of primary 13 PTC and 8 ATC speci-
mens from the University of Colorado Hospital path-
ology archives for analysis of TXNIP protein expression
by immunohistochemistry. Institutional review board
approval was obtained. Sections were deparaffinized in
Histoclear, rehydrated, and antigen retrieval in 10 mM
sodium citrate buffer with 0.05% Tween 20, pH 6.0, was
performed in a Biocare Medical decloaking chamber at
120°C for 5 minutes. Endogenous peroxidase activity was
quenched by incubation in 3% hydrogen peroxide for
30 minutes at room temperature. Tissues were blocked
with 5% goat serum in phosphate-buffered saline (PBS)
with 1% bovine serum albumin for 1 hour at room
temperature. Slides were incubated overnight at 4°C in
primary anti-TXNIP antibody at a concentration of 1:400
(mouse monoclonal antibody IgG1, clone JY2, MBL Inter-
national, catalog # K0205) diluted in antibody dilution
buffer (0.01 M PBS, pH 7.2 with 0.05% sodium azide) or
normal mouse IgG at an equivalent concentration as nega-
tive control (Santa Cruz Biotechnology, catalog # sc-2025).
Slides were incubated in secondary goat anti-mouse anti-
body conjugated to horseradish peroxidase diluted in PBS
at a concentration of 1:400 (Dako, catalog # P0447) for
1 hour at room temperature. For visualization, slides were
incubated at room temperature for 2–4 minutes in
ImmPACT 3, 3′-diaminobenzidine (DAB) peroxidase sub-
strate (Vector Laboratories). Sections were counterstained
in Mayer’s hematoxylin solution, dehydrated, dried, and
mounted with Cytoseal (Thermo Scientific). Stained speci-
mens were read and score by a pathologist (S. B. Sams)
based on percent of specimen that stained positively and
degree of intensity (0 to 3+).
TXNIP overexpression
A plasmid encoding human TXNIP (pcDNA3.1-hTXNIP)
was a kind gift from P. Patwari (Brigham and Women’s
Hospital, Boston, MA). The TXNIP coding sequence was
amplified via polymerase chain reaction (PCR), using
primers TXNIP 1 F [5′ TAG CGG CCG CAT GGT GAT
GTT CAA GAA GAT CAA GT 3′] and hTXNIP EcoRI
rev [5′ GCG AAT TCT CAC TGC ACA TTG TTG TTG
AGG A 3′], which added a NotI restriction site to the
5′ end and an EcoRI site on the 3′ end of the coding se-
quence, respectively. PCR product was ligated into the
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EcoRI digestion, gel purified, and directionally inserted
into the retroviral vector pQCXIP (gift of S. Nordeen, Uni-
versity of Colorado Denver, Aurora, CO) pre-digested with
NotI and EcoRI. Resultant pQCXIP-hTXNIP clones were
confirmed with sequencing. Retrovirus was generated in
the BOSC cell line [52] after transfection of pQCXIP or
pQCXIP-hTXNIP with pCL-Ampho packaging vector (gift
of H. Ford, University of Colorado Denver, Aurora, CO)
using FuGENE 6 transfection reagent (Roche). Super-
natant with virus was collected at 48 and 72 hours after
transfection, centrifuged at low speed, filtered through
0.45 μm syringe filter (Fisher Scientific), and stored at
−80°C. Anaplastic HTh74 and T238 cells were trans-
duced with virus-containing supernatant mixed 1:1 with
growth media and supplemented with 8 μg/mL poly-
brene (Sigma-Aldrich), as previously described [4]. In
the vector pQCXIP, the coding sequence for the insert
(TXNIP) is cotranscribed with a puromycin resistance
gene as a bicistronic message via an internal ribosome
entry site. Forty-eight hours after transduction, the cells
were placed under selection in puromycin (Sigma-Al-
drich) at a concentration of 0.5 μg/mL for HTh74 cells
and 2.5 μg/mL for T238 cells as previously determined
by kill curves.
Glucose uptake assays
Cells were grown in 12-well plates with each condition
plated in triplicate. Prior to glucose uptake determin-
ation, cells were rinsed in PBS, then incubated in low
glucose DMEM without serum for 4 hours at 37°C. Cells
were then incubated in Krebs buffer (140 mM NaCl,
5 mM potassium chloride, 2.5 mM magnesium sulfate,
1 mM calcium chloride, 20 mM HEPES, pH 7.4) sup-
plemented with dimethyl sulfoxide (DMSO) or 20 μM
cytochalasin B (Sigma-Adrich), an actin polymerization
inhibitor that blocks nonspecific glucose uptake, for
1 hour at 37°C. Next, the cells were incubated in 0.01 mM
2-deoxy-D-glucose [Sigma-Aldrich], 0.665 nCi/mL [1,2-3H]
2-deoxy-D-glucose [PerkinElmer], and either DMSO or
cytochalasin B (20 μM) in Krebs buffer for an additional
20 minutes at 37°C. After this time period, cells were
immediately rinsed 3 times with ice-cold PBS, then
lysed in 0.4 N sodium hydroxide. Base was subsequently
neutralized with 0.4 N hydrochloric acid. Uptake of
[3H]2-deoxy-D-glucose was determined by scintillation
counting (Beckman Coulter). Nonspecific glucose up-
take as determined by the cytochalasin B group was
subtracted, and glucose uptake in pmol was normalized
to protein content as determined by the BioRad DC
protein assay system. Experiments were performed at
least 3 times with each cell line and condition in tripli-
cate, and data were graphed and analyzed by t-test using
GraphPad Prism software.Viable cell proliferation assays
HTh74 and T238 cells stably expressing pQCXIP vector
with or without TXNIP were plated in duplicate in 6 cm
plates at 50,000 cells/plate in RPMI 1640 supplemented
with 5% FBS, without antibiotics. At days 3, 5, and 7, cells
were rinsed in PBS, incubated in 0.25% trypsin-EDTA, col-
lected, and resuspended in RPMI with 5% FBS. Cells were
counted via the ViCell automated cell counting system.
On day 7, collected cells were subsequently lysed in
EB and subjected to Western blot analysis to determine
TXNIP protein expression. Experiments were performed
at least 3 times, and data were combined, graphed, and an-
alyzed by 2 way ANOVA using GraphPad Prism software.Invasion assays
Invasion assays with 2×105 HTh74 and 1×105 T238 cells
stably expressing QCXIP vector with or without TXNIP
were performed as previously described using BD Biocoat
Matrigel invasion chambers (8 μM pore size, 24-well; BD
Biosciences) [4]. Five fields per well were counted using
Metamorph software (Molecular Devices), and each con-
dition was performed in triplicate. Data from three inde-
pendent experiments were combined, and data averages
were normalized to the vector control mean. Statistical
analysis was performed via application of the two-tailed
t-test using GraphPad Prism software.Orthotopic tumor mouse model
The right thyroid lobes of athymic nude mice were
injected with 500,000 T238 QCXIP and T238 TXNIP cells
stably expressing a luciferase-IRES-GFP plasmid (pEGFP-
Luc-N1, a kind gift from C. Li, University of Colorado
Denver, Aurora, CO) in 5 μL PBS as previously described
[4,38-41]. Weekly bioluminescence imaging using Xeno-
gen IVIS200 (Caliper Life Sciences) in the presence of
injected luciferin substrate (Caliper Life Sciences) was per-
formed to monitor tumor establishment and growth, and
bioluminescence activity was analyzed using Living Image
software (Xenogen Corporation). Bioluminescence curves
were analyzed by 2-way ANOVA with Bonferroni post-
tests using GraphPad Prism software. There were 10–11
mice per group for each experiment, and the described
experiment was performed two times. In toto, there were
21 mice in each experimental arm when data from the
two independent studies were pooled. Animals were sacri-
ficed at 26–28 days or sooner if ill or moribund, and final
tumor dimensions were measured with calipers. Final
tumor volumes were calculated using the formula (length ×
width × height)/0.5236 and compared with t-test using
GraphPad Prism software. All procedures were conducted
in accordance with a protocol approved by the Institutional
Animal Care and Use Committee of the University of
Colorado Denver.
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transcription polymerase chain reaction (qRT-PCR) for
eGFP expression
At time of sacrifice for the second mouse orthotopic injec-
tion experiment, lungs were collected, snap-frozen in liquid
nitrogen, and stored at −80°C. Lungs from uninjected mice
served as negative controls. To harvest RNA, lung tissues
were diced in a petri dish on ice and homogenized in TRI
Reagent (Sigma Aldrich) using sterile stainless steel beads
and a Qiagen TissueLyser. Homogenized tissue in TRI
Reagent (1 mL) was mixed with 200 μL chloroform, centri-
fuged, and aqueous phase (which contains RNA) was re-
moved. RNA purification with Qiagen RNeasy kit was then
performed per the manufacturer’s instructions with the ex-
ception of an added step of column incubation with RNase-
free DNase I stock solution (Qiagen) in between wash steps
to remove any residual DNA. RNA was ultimately eluted
with RNase free water, and RNA concentration was quanti-
tated using a Synergy H1 microplate reader (BioTek).
GFP mRNA levels were measured by real-time qRT-
PCR using an ABI Prism 7900 sequence detector (Applied
Biosystems/Life Technologies). Primers and probe for
GFP were designed with the assistance of the Prism
7900 sequence detection software (Primer Express, PE
Applied Biosystems). The TaqMan probe was purchased
from Life Technologies 5′ labeled with 6-carboxyfluo
rescein (FAM) and 3′-labeled with 6-caboxy-tetramethyl
rhodamine (TAMRA). The forward and reverse primer se-
quences were GFP- F 5′- CACATGGTCCTGCTGGA
GTTC- 3′ and GFP- R 5′- TTGTACAGCTCGTCCAT
GCC- 3′ and the TaqMan fluorogenic probe sequence was
6FAM-CCGCCGCCGGGATCACTCT-TAMRA. Amplifi-
cation reactions were performed in MicroAmp optical
plates (Applied Biosystems/Life Technologies) in a 20 μl
mix containing 1X TaqMan Buffer A (500 mM KCl,
100 mM Tris–HCl, 0.1 M EDTA, 600 nM passive refer-
ence dye ROX, pH 8.3 at room temperature), 300 μM
each of dATP, dGTP, dCTP and 600 μM dUTP, 5.5 mM
magnesium chloride, 900 nM forward primer, 900 nM
reverse primer, 200 nM probe, 1.25 U AmpliTaq Gold
DNA Polymerase and the template cDNA. Thermal cycling
conditions were as follows: 2 minutes at 50°C followed by
activation of TaqGold at 95°C for 10 minutes. Subsequently,
40 cycles of amplification were performed at 95°C for
15 seconds and 60°C for 1 minute. Quantities of GFP in test
samples were normalized to 18 s r-RNA (PE Applied Bio-
systems), and the Mann Whitney test was applied to assess
for statistical significance using GraphPad Prism software.
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